Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
The building was once the tallest in Iran's capital and was on fire for several hours before it collapsed.
Vegetable lovers across the UK will be met with possible despair when they attempt to purchase the humble courgette from a supermarket.
Addressing the World Economic Forum, Theresa May said citizens voted for a "truly global Britain" when they opted to leave the EU.